Shattuck Labs (STTK) Corporate presentation summary

Strategic focus and mission

• Developing novel biologics targeting autoimmune, inflammatory, and other serious diseases, with a focus on TNF receptor modulation.

• Mission centers on scientific excellence, urgency, and resource stewardship to deliver innovative medicines.

• Vision emphasizes challenging conventional approaches to create impactful therapeutics.

Pipeline and lead program

• Lead candidate SL-325 is a potential first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), showing picomolar binding affinity and superior preclinical efficacy compared to TL1A-blocking antibodies.

• Pipeline includes bispecific DR3 antibodies for IBD and other autoimmune diseases, and bifunctional fusion proteins for oncology.

• IND-enabling work for SL-325 is ongoing, with IND filing expected in Q3 2025 and initial clinical data anticipated in 2026.

Scientific rationale and competitive landscape

• DR3 is constitutively expressed in inflamed and non-inflamed gut tissue, enabling durable receptor blockade and potentially higher rates of endoscopic remission.

• SL-325 blocks TL1A binding to DR3 with ~10-fold greater potency than benchmark anti-TL1A antibodies in vitro and efficiently inhibits IFNy secretion in both healthy and IBD patient samples.

• Competitors focus on TL1A ligand blockade, while SL-325 uniquely targets the DR3 receptor, potentially avoiding immune complex formation and allowing for co-targeting strategies.